Welcome to the News Room

From compulsory licensing to voluntary transfer?

Posted by:

Bristol-Myers Squibb announced a technology transfer agreement with the Brazilian Ministry of Health to expand access to the HIV drug atazanavir. The agreement is designed to build the capacity and skills required for the Brazilian government to become, over time, the sole manufacturer of atazanavir in Brazil.

Does this mark a shift in Brazil’s HIV/AIDS pharmaceutical policy, which in the past was marked by aggressive negotiation with manufacturers and threats of compulsory licensing?

For further details, see:





About the Author:

Rachel specialises in biomedical and energy-related innovation as well as international innovation policy. She has particular experience in sector-specific trend mapping, survey building and benchmarking of intellectual property environments. Rachel’s work focuses on Europe, with special emphasis on the UK and Spain, and she speaks fluent Spanish. She gained direct experience with UK innovation policy while interning with the UK’s then Department for Innovation, Universities and Skills.
  Related Posts
  • No related posts found.